Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes  

作　　者：Li-Nong JI Yun-Dai CHEN Jing LIU Xiang-Hai ZHOU 

机构地区：[1]Cardiovascular Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare [2]Peking University People's Hospital [3]Chinese PLA General Hospital

出　　处：《Journal of Geriatric Cardiology》2024年第7期689-702,共14页老年心脏病学杂志（英文版）

摘　　要：The prevalence of patients with coronary heart disease(CHD)and diabetes mellitus is notably high,posing sig-nificant residual cardiovascular risks even after routine interventions such as antihypertensive,lipid-lowering,and antithrombot-ic treatments.Recent studies have demonstrated that certain glucose-lowering medications confer cardiovascular benefits for pa-tients with type 2 diabetes.However,a survey indicates that cardiologists may not be fully acquainted with the optimal screen-ing timing,indicators,and diagnostic criteria for type 2 diabetes,and there is insufficient awareness and a low rate of prescrip-tion of novel glucose-lowering medications with proven cardiovascular efficacy,such as glucagon-like peptide-1 receptor agon-ists(GLP-1 RAs)and sodium-glucose co-transporter-2 inhibitors(SGLT-2i).In this context,based on domestic and international guidelines or consensus and the latest evidence-based evidence,this consensus aims to standardize the glycemic management for patients with acute coronary syndrome,chronic coronary syndrome,and perioperative management for percutaneous coronary intervention.It highlights the key points of screening and diagnosis of type 2 diabetes,and the comprehensive management of cardiovascular risk in patients with CHD.The consensus elaborates on the principles and algorithms of glycemic management for CHD patients,without involving acute complications of diabetes,clarifies the clinical practice of glucose-lowering medications with cardiovascular benefits,and promotes the standardized use of these medications in cardiovascular and other related spe-cialty fields.Additionally,it addresses the glucose-lowering treatment to comprehensively reduce cardiovascular risks.

关 键 词：CORONARY PATIENTS ROUTINE 

分 类 号：R587.2[医药卫生—内分泌] R541.4[医药卫生—内科学]